ISG15 is associated with cervical cancer development

Tao,Pingping; Sun,Liyan; Sun,Yanmei; Wang,Yuhua; Yang,Yumei; Yang,Binlie; Li,Fang

doi:10.3892/ol.2022.13500

ISG15 is associated with cervical cancer development

Authors:
- Pingping Tao
- Liyan Sun
- Yanmei Sun
- Yuhua Wang
- Yumei Yang
- Binlie Yang
- Fang Li
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Pudong New Area People's Hospital Affiliated to Shanghai Health University, Shanghai 201299, P.R. China, Department of Obstetrics and Gynecology, East Hospital, Tongji University School of Medicine, Shanghai 201999, P.R. China
Published online on: September 12, 2022 https://doi.org/10.3892/ol.2022.13500
Article Number: 380
Copyright: © Tao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer (CC) is a complex disease. Numerous factors contribute to the tumourigenesis and progression of CC neoplasms. The present study analysed transcriptomic differences and simulated tumour progression to explore the pathogenesis of CC. RNA sequencing was performed to analyse the transcriptomic differences among normal tissue (NC), paracarcinoma tissue (TP), and primary tumour tissue (TT). Pseudo‑time analysis was performed to simulate tumour progression. Reverse transcription‑quantitative PCR (RT‑qPCR) and immunohistochemistry (IHC) were used to analyse the expression levels of ISG15 ubiquitin‑like modifier (ISG15). Cell proliferation wound healing and Transwell assays were used to examine the effect of ISG15 inhibition and overexpression on HeLa cells. The RT‑qPCR and IHC results indicated that ISG15 expression was significantly upregulated in TT. An increasing trend of ISG15 expression from NC to TP to TT was observed, which suggested that elevated ISG15 expression was closely associated with malignant evolution in CC tissues. HeLa cell experiments revealed that ISG15‑small interfering RNA inhibited cell proliferation and invasion. The present study demonstrated that ISG15 was upregulated in CC and positively associated with the development of CC. ISG15 may act as an oncogene in the tumourigenesis of CC.

View Figures

View References

1	Cohen PA, Jhingran A, Oaknin A and Denny L: Cervical cancer. Lancet. 393:169–182. 2019. View Article : Google Scholar : PubMed/NCBI
2	Li H, Wu X and Cheng X: Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 27:e432016. View Article : Google Scholar : PubMed/NCBI
3	Wang H, Zhao Y, Chen M and Cui J: Identification of novel long non-coding and circular RNAs in human papillomavirus-mediated cervical cancer. Front Microbiol. 8:17202017. View Article : Google Scholar : PubMed/NCBI
4	Choi YJ and Park JS: Clinical significance of human papillomavirus genotyping. J Gynecol Oncol. 27:e212016. View Article : Google Scholar : PubMed/NCBI
5	Stanley MA: Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 25:215–222. 2012. View Article : Google Scholar : PubMed/NCBI
6	Hong S, Mehta KP and Laimins LA: Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J Virol. 85:9486–9494. 2011. View Article : Google Scholar : PubMed/NCBI
7	Li X, Tian R, Gao H, Yang Y, Williams BRG, Gantier MP, McMillan NAJ, Xu D, Hu Y and Gao Y: Identification of a histone family gene signature for predicting the prognosis of cervical cancer patients. Sci Rep. 7:164952017. View Article : Google Scholar : PubMed/NCBI
8	Brant AC, Menezes AN, Felix SP, de Almeida LM, Sammeth M and Moreira MAM: Characterization of HPV integration, viral gene expression and E6E7 alternative transcripts by RNA-Seq: A descriptive study in invasive cervical cancer. Genomics. 111:1853–1861. 2019. View Article : Google Scholar : PubMed/NCBI
9	Gong Z, Liu J, Xie X, Xu X, Wu P, Li H, Wang Y, Li W and Xiong J: Identification of potential target genes of USP22 via ChIP-seq and RNA-seq analysis in HeLa cells. Genet Mol Biol. 41:488–495. 2018. View Article : Google Scholar : PubMed/NCBI
10	Yu B, Chen L, Zhang W, Li Y, Zhang Y, Gao Y, Teng X, Zou L, Wang Q, Jia H, et al: TOP2A and CENPF are synergistic master regulators activated in cervical cancer. BMC Med Genomics. 13:1452020. View Article : Google Scholar : PubMed/NCBI
11	Xu YP, Wang ZQ, Liang XD, Wang Y and Wang JL: Comparative analysis of the prognosis of patients with locally advanced cervical cancer undergoing laparoscopic or abdominal surgery. Zhonghua Fu Chan Ke Za Zhi. 55:609–616. 2020.(In Chinese). PubMed/NCBI
12	Berek JS, Matsuo K, Grubbs BH, Gaffney DK, Lee SI, Kilcoyne A, Cheon GJ, Yoo CW, Li L, Shao Y, et al: Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri. J Gynecol Oncol. 30:e402019. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Anaya J: OncoLnc: Linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput Sci. 2:e672016. View Article : Google Scholar
15	Durfee LA, Lyon N, Seo K and Huibregtse JM: The ISG15 conjugation system broadly targets newly synthesized proteins: Implications for the antiviral function of ISG15. Mol Cell. 38:722–732. 2010. View Article : Google Scholar : PubMed/NCBI
16	Cannella F, Scagnolari C, Selvaggi C, Stentella P, Recine N, Antonelli G and Pierangeli A: Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women. Med Microbiol Immunol. 203:177–184. 2014. View Article : Google Scholar : PubMed/NCBI
17	Pierangeli A, Degener AM, Ferreri ML, Riva E, Rizzo B, Turriziani O, Luciani S, Scagnolari C and Antonelli G: Interferon-induced gene expression in cervical mucosa during human papillomavirus infection. Int J Immunopathol Pharmacol. 24:217–223. 2011. View Article : Google Scholar : PubMed/NCBI
18	Rajkumar T, Sabitha K, Vijayalakshmi N, Shirley S, Bose MV, Gopal G and Selvaluxmy G: Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer. 11:802011. View Article : Google Scholar : PubMed/NCBI
19	Desai SD, Reed RE, Burks J, Wood LM, Pullikuth AK, Haas AL, Liu LF, Breslin JW, Meiners S and Sankar S: ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med (Maywood). 237:38–49. 2012. View Article : Google Scholar : PubMed/NCBI
20	Kiessling A, Hogrefe C, Erb S, Bobach C, Fuessel S, Wessjohann L and Seliger B: Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene. 28:2606–2620. 2009. View Article : Google Scholar : PubMed/NCBI
21	Li C, Wang J, Zhang H, Zhu M, Chen F, Hu Y, Liu H and Zhu H: Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma. Oncotarget. 5:8429–8441. 2014. View Article : Google Scholar : PubMed/NCBI
22	Wood LM, Pan ZK, Seavey MM, Muthukumaran G and Paterson Y: The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunol Immunother. 61:689–700. 2012. View Article : Google Scholar : PubMed/NCBI
23	Swaim CD, Scott AF, Canadeo LA and Huibregtse JM: Extracellular ISG15 signals cytokine secretion through the LFA-1 integrin receptor. Mol Cell. 68:581–590.e5. 2017. View Article : Google Scholar : PubMed/NCBI
24	D'Cunha J, Knight E Jr, Haas AL, Truitt RL and Borden EC: Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci USA. 93:211–215. 1996. View Article : Google Scholar : PubMed/NCBI
25	Forys JT, Kuzmicki CE, Saporita AJ, Winkeler CL, Maggi LB Jr and Weber JD: ARF and p53 coordinate tumor suppression of an oncogenic IFN-β-STAT1-ISG15 signaling axis. Cell Rep. 7:514–526. 2014. View Article : Google Scholar : PubMed/NCBI
26	Hadjivasiliou A: ISG15 implicated in cytoskeleton disruption and promotion of breast cancer. Expert Rev Proteomics. 9:72012.
27	Cerikan B and Schiebel E: DOCK6 inactivation highlights ISGylation as RHO-GTPase balancer. Cell Cycle. 16:304–305. 2017. View Article : Google Scholar : PubMed/NCBI
28	Burks J, Reed RE and Desai SD: ISGylation governs the oncogenic function of Ki-Ras in breast cancer. Oncogene. 33:794–803. 2014. View Article : Google Scholar : PubMed/NCBI
29	Qiu X, Hong Y, Yang D, Xia M, Zhu H, Li Q, Xie H, Wu Q, Liu C and Zuo C: ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Int J Clin Exp Med. 8:17140–17150. 2015.PubMed/NCBI
30	Yan W, Shih JH, Rodriguez-Canales J, Tangrea MA, Ylaya K, Hipp J, Player A, Hu N, Goldstein AM, Taylor PR, et al: Identification of unique expression signatures and therapeutic targets in esophageal squamous cell carcinoma. BMC Res Notes. 5:732012. View Article : Google Scholar : PubMed/NCBI